<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132878">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371968</url>
  </required_header>
  <id_info>
    <org_study_id>Alfentanil LMA</org_study_id>
    <nct_id>NCT01371968</nct_id>
  </id_info>
  <brief_title>Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia</brief_title>
  <official_title>Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malaysian Society of Anaesthesiologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the optimal dose of alfentanil in suppressing the airway
      reflexes during supreme LMA removal in anaesthetized adult.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The removal of LMA may be associated with coughing, biting, agitation and airway
      complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient
      is breathing spontaneously and when the airway reflexes are still depressed. A number of
      techniques have been used to prevent this adverse emergence phenomenon, such as removing the
      tube while the patient is in deep plane of anaesthesia or administration of local
      anaesthetic and intravenous opioids

      The administration of intravenous opioids before emergence may be useful for preventing
      cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and
      agitation during the endotracheal tube emergence. However, its use in suppressing cough in
      LMA patient has not been evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">November 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nunber of patient with airway complication</measure>
    <time_frame>after administration of alfentanil and within 1 min of LMA removal</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Airway Response</condition>
  <arm_group>
    <arm_group_label>alfentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alfentanil</intervention_name>
    <description>Alfentanil is administered intravenously at the end of surgery.</description>
    <arm_group_label>alfentanil</arm_group_label>
    <other_name>Rapifen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ASA I and II patients

          2. Age 18 to 49 years old

          3. Minor elective day care surgery (&gt; 20 minute and less than 2 hours) which require
             local anaesthetic infiltration and does not require use of long acting opioids.

        Exclusion Criteria:

          1. Potential difficult airway

          2. Reactive airway disease or sign and symptoms of upper respiratory tract infection.

          3. History of cardiac, pulmonary and renal diseases

          4. Body Mass Index &gt; 30 kgm2.

          5. Risk of aspiration.

          6. Poor dentition with high risk of damage.

          7. Patient refusal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Chew Kiok, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anaesthesiogy, UMMC.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lee Chew Kiok, MBBS</last_name>
    <phone>0162737229</phone>
    <email>cklee1127@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Chew Yin</last_name>
    <phone>0192340232</phone>
    <email>wangcy1836@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Lembah Pantai</city>
        <state>Kuala Lumpur</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Chew Kiok, MBBS</last_name>
      <phone>0162737229</phone>
      <email>cklee1127@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Wang Chew Yin</last_name>
      <phone>0192340232</phone>
      <email>wangcy1836@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lee Chew Kiok, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 10, 2011</lastchanged_date>
  <firstreceived_date>May 4, 2011</firstreceived_date>
  <responsible_party>
    <name_title>Dr Lee Chew Kiok</name_title>
    <organization>University Malaya Medical centre</organization>
  </responsible_party>
  <keyword>Alfentanil</keyword>
  <keyword>optimal dose</keyword>
  <keyword>laryngeal mask airway</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Alfentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
